Breaking News

Vectura, Kinaset Partner to Develop Asthma Treatment

Licenses VR588 to Kinaset, Vectura will provide formulation development services to support Phase I studies and ultimately commercialization.

By: Contract Pharma

Contract Pharma Staff

Vectura Group plc, an inhalation CDMO, has signed a global license and development agreement with Kinaset Therapeutics Inc. for the development and commercialization of VR588, a preclinical novel inhaled pan-JAK inhibitor for the prevention and treatment of severe asthma. VR588 was previously developed by Vectura. This agreement provides an opportunity for Vectura to realize value from its research and investment in VR588, while expanding its CDMO development services portfolio by supporting...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters